Treatment
Upadacitinib clinical trials
We’re tracking 36 recruiting studies that include Upadacitinib, each written for real people, not researchers, below.
Recruiting studies
- NCT06687551RecruitingPhase 4
Testing lower doses of JAK inhibitors for rheumatoid arthritis
This study tests whether people with rheumatoid arthritis whose disease is well controlled can safely take a lower dose of their JAK inhibitor medication. It aims to see if reducing the dose still keeps inflammation down and prevents flare-ups.
Toulouse, OccitanieAges 18–65 - NCT06712628Recruiting
Comparing how long people stay on upadacitinib vs TNF inhibitors for RA
This study compares how well people with rheumatoid arthritis stay on two types of medicines: upadacitinib (Rinvoq) and TNF inhibitors. It looks at real-world experiences in Germany to see if one medicine is more likely to be continued over time.
Freiburg im Breisgau, Baden-WurttembergAges 18 years+ - NCT06379958RecruitingPhase 1
Drug interaction study of leramistat in healthy adults
This study tests how a drug called leramistat interacts with other medicines. It's for healthy adults who cannot get pregnant or make someone pregnant.
BelfastAges 18–55 - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT06573593Recruiting
JAK inhibitors for children with alopecia areata
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Hangzhou, ZhejiangAges 2–80 - NCT06581042Recruiting
Study of upadacitinib in adults with IBD in Belgium
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
Bonheiden, AntwerpenAges 18 years+ - NCT06660693RecruitingPhase 3
Comparing rescue treatments for severe ulcerative colitis flare
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
Hamilton, OntarioAges 18–64 - NCT06838845Recruiting
A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Guangzhou, GuangdongAges 18 years+ - NCT06937788Recruiting
Atopic dermatitis trial using existing registry data
This trial looks at how well two eczema treatments work by using data from a patient registry. It may help people with moderate to severe eczema who have had symptoms for at least 3 years.
Dresden, SaxonyAges 18 years+ - NCT07073079Recruiting
Study of upadacitinib and risankizumab for Crohn's after first therapy
This study tests two oral/ injectable medicines (upadacitinib and risankizumab) in adults with moderate-to-severe Crohn's who have already tried a TNF-blocker. It aims to see how well these treatments work in everyday practice.
Castellana Grotte, BariAges 18 years+ - NCT07166315Recruiting
Comparing new treatments for arthritis of the spine or joints
This study looks at how well different newer medications work for people with axial spondyloarthritis or psoriatic arthritis. It focuses on those just starting treatment with bimekizumab, risankizumab, guselkumab, upadacitinib, or a TNF inhibitor.
Bath, SomersetAges 18 years+ - NCT03358693Recruiting
Study of inflammation patterns in chronic skin diseases
This study looks at molecular (body-level) signatures in people with chronic inflammatory skin conditions. You may help researchers understand what drives inflammation, while receiving standard (already approved) systemic treatment through routine care.
KielAges Any age
Common questions
- Are there clinical trials studying Upadacitinib?
- Yes. Clin2 currently lists 36 recruiting studies that include Upadacitinib, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Upadacitinib trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Upadacitinib an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Upadacitinib or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.